Watch Live

Tweet TWEET

Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based

    Nektar to Announce Financial Results for the Third Quarter of 2013 on
   Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets

PR Newswire

SAN FRANCISCO, Oct. 30, 2013

SAN FRANCISCO, Oct. 30, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:
NKTR) will announce its financial results for the third quarter ended
September 30, 2013 on Thursday, November 7, 2013, after the close of
U.S.-based financial markets. Howard Robin, president and chief executive
officer, will host a conference call to review the results beginning at 5:00
p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be
accessed through a link that is posted on the home page and Investor Relations
section of the Nektar website: http://www.nektar.com. The web broadcast of the
conference call will be available for replay through Monday, December 9, 2013.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 91919000 (Nektar Therapeutics is the host)

In the event that any non-GAAP financial measure is discussed on the
conference call that is not described in the press release, or explained on
the conference call, related information will be made available on the
Investor Relations page at the Nektar website as soon as practical after the
conclusion of the conference call.

About Nektar
Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company developing
novel therapeutics based on its PEGylation and advanced polymer conjugation
technology platforms. Nektar has a robust R&D pipeline of potentially
high-value therapeutics in oncology, pain and other therapeutic areas. In the
area of pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which
has completed Phase 3 development as a once- daily, oral tablet for the
treatment of opioid-induced constipation. For naloxegol, an MAA has been
accepted for filing in Europe, and an NDA has been submitted for filing in the
U.S. This agreement also includes NKTR-119, an earlier stage development
program that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel
mu-opioid analgesic molecule for chronic pain conditions, has completed Phase
2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a
novel mu-opioid analgesic molecule in development to treat acute pain is in
Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is
being evaluated in a Phase 3 clinical study (the BEACON study) for the
treatment of metastatic breast cancer and is also in a number of Phase 2
studies. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted
by Bayer Healthcare to treat patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe
through partnerships with leading biopharmaceutical companies, including UCB's
Cimzia^® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS^® for
hepatitis C and Amgen's Neulasta^® for neutropenia. Additional
development-stage products that leverage Nektar's proprietary technology
platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program,
which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama and Hyderabad, India. Further information
about the company and its drug development programs and capabilities may be
found online at http://www.nektar.com.

Nektar Investor & Media Inquiries
Jennifer Ruddock/Nektar Therapeutics (415) 482-5585

SOURCE Nektar Therapeutics

Website: http://www.nektar.com
 
Press spacebar to pause and continue. Press esc to stop.